OABI

OmniAb Inc.
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$333.44M
P/E Ratio
EPS
$-0.46
Beta
1.17
52W High
$2.79
52W Low
$1.30
50-Day MA
$2.18
200-Day MA
$1.84
Dividend Yield
Profit Margin
-187.60%
Forward P/E
PEG Ratio

About OmniAb Inc.

OmniAb Inc. is a pioneering biotechnology firm focused on the creation of fully human therapeutic antibodies through its cutting-edge OmniAb platform. This proprietary technology facilitates the rapid identification and optimization of potent therapies for a diverse range of diseases, enhancing the potential for successful clinical outcomes. By fostering strategic collaborations and partnerships, OmniAb accelerates its drug development processes while improving access to transformative treatments. With a highly experienced leadership team and a promising pipeline of product candidates, the company is well-positioned to leverage the expanding opportunities within the biopharmaceutical sector.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$28.94M
Gross Profit (TTM)$28.62M
EBITDA$-33.44M
Operating Margin-54.30%
Return on Equity-20.30%
Return on Assets-11.30%
Revenue/Share (TTM)$0.24
Book Value$1.81
Price-to-Book1.34
Price-to-Sales (TTM)11.52
EV/Revenue11.11
EV/EBITDA-10.62
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)247.30%
Shares Outstanding$144.97M
Float$113.85M
% Insiders15.33%
% Institutions50.96%

Historical Volatility

HV 10-Day
63.80%
HV 20-Day
78.12%
HV 30-Day
77.27%
HV 60-Day
76.94%
HV Rank
91.7%

Volatility is currently contracting

Analyst Ratings

Consensus ($7.33 target)
7
Buy

Latest News

OmniAb Q1 Earnings Call Highlights

OmniAb NASDAQ: OABI reported first-quarter 2026 results that management characterized as a “very strong start to the year,” driven primarily by clinical progress across its partner portfolio and associated milestone revenue. Get OmniAb alerts:Sign UpPartner program progress drives revenue outperformance President and CEO Matt Foehr said the company continues to see partner programs derived from OmniAb's technologies move into the clinic and into later-stage development, which he described as the point where the licensing model translates into “clearer and more visible value” through potential future milestones and royalties.

MarketBeat5/8/2026Positive
OmniAb Reports First Quarter 2026 Financial Results and Business Highlights

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2026, provided operating and partner program updates, and increased 2026 financial guidance. “OmniAb experienced strong momentum during the first quarter as multiple partnered programs advanced into later-stage clinical development, reinforcing the diversity and value of our portfolio. With a very strong start to the year, we are raising our 2026 revenue guidanc.

Business Wire5/7/2026Neutral
OmniAb to Participate in Three Upcoming Investor Conferences

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in three investor conferences over the coming weeks. H.C. Wainwright 2nd Annual Royalty Company Virtual Conference, May 6. Management will participate in a fireside chat on Wednesday, May 6th. Benchmark 6th Annual Healthcare House Call Virtual Investor Conference, May 28. Management will hold virtual one-on-one and small group meetings with investors on Thursday, May 28th. Jeff.

Business Wire4/24/2026Neutral
OmniAb to Report First Quarter 2026 Financial Results on May 7

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three months ended March 31, 2026, after the close of the U.S. financial markets on Thursday, May 7, 2026, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What:   OmniAb conference call to discuss first quarter 2026 financial results and business updates       Date:   Thursday, May 7, 2026       Time:   4:30 p.m. Easter.

Business Wire4/21/2026Neutral

More HEALTHCARE Stocks

Data last updated: 7/9/2026